Varian Medical wins FDA nod for Halcyon radiotherapy cancer treatment system

Varian Medical (NYSE:VAR) said today it won FDA 510(k) clearance for its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system. The Palo Alto, Calif.-based company said its Halcyon IMRT system features improvements that make it more comfortable for patients and streamline operator’s workflow, only requiring 9 steps from start to treatment, down from 30 steps in legacy machines. “We are proud that Halcyon has now received both 510(k) clearance and CE mark. With its human-centered and user-friendly design, Halcyon is engineered to revolutionize clinical workflow. These two clearances are very important milestones in the availability of this new system and advancing cost-effective cancer care worldwide,” Varian oncology systems biz prez Kolleen Kennedy said in a press release. Varian Medical said the device is designed to handle “the majority” of cancer patients, including individuals with prostate, breast, head &neck and other forms of cancer. The system requires the company’s Eclipse 15.1.1 treatment planning software, which is currently pending 510(k) approval. In May, Varian Medical said it won Shonin approval from the Japanese Ministry of Health, Labor and Welfare for its ProBeam system designed for proton therapy. The post Varian Medical wins FDA nod for Halcyon radiotherapy cancer treatment system appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: 510(k) Food & Drug Administration (FDA) Oncology Regulatory/Compliance Varian Medical Systems Source Type: news

Related Links:

It is critical that rigorous evaluation of technology in radiation oncology be undertaken during the early stages of implementation or when there is a marked cost differential. Prospective clinical data proving the clinical effectiveness of emerging technology may not be available to guide proper investment and development. In these scenarios, models can be used to simulate expected clinical outcomes and predict comparative effectiveness and cost-effectiveness.1 In this edition of the Red Journal, 2 studies use model-based approaches to compare photon intensity modulated radiation therapy (IMRT) to proton beam therapy (PBT...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
1139Introduction: Thoracic malignancies are among the most common malignancies diagnosed both in the United States and worldwide. Radiation therapy (RT) plays an important role in the treatment of thoracic malignancies. Depending on the primary disease site and tumor stage, RT can be used as monotherapy, or as part of multimodality therapy for curative intent, or for palliative reduction of advanced disease. In fact, more than 50% of all patients with thoracic malignancies will receive RT as part of their multidisciplinary care. 18F-Fluorodeoxyglucose positron emission tomography (PET) is commonly used for initial cancer d...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Educational Exhibit Posters Source Type: research
Abstract The purpose of this study was the evaluation of the impact of a variable relative biological effectiveness (RBE) compared to a constant RBE value of 1.1 in proton therapy prostate trials due to uncertainties in α/β ratio.
 
 Twenty patients receiving passive scattered proton therapy (PSPT) and fifteen patients receiving intensity modulated proton therapy (IMPT) were compared to twenty patients treated with 7-field intensity modulated photon therapy (IMRT). For proton beam therapy (PBT), the RBE was estimated using two different RBE models. Tumor control probabilities (TCP) and n...
Source: Physics in Medicine and Biology - Category: Physics Authors: Tags: Phys Med Biol Source Type: research
CONCLUSIONS: IMPT with FGBH and CT-on-rail guidance is a robust treatment approach for liver tumor cases. PMID: 31005203 [PubMed - in process]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
CONCLUSIONS: The selection of lymph node target volumes for head and neck cancers treated with IMRT/VMAT or other highly conformal techniques (e.g. proton therapy) requires a rigorous approach. This updated proposal of selection should help clinicians for the selection of lymph nodes target volumes and contribute to increase consistency. PMID: 31005201 [PubMed - in process]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
We report the early clinical outcomes and toxicities of intensity-modulated proton therapy (IMPT) vs. intensity-modulated radiation therapy (IMRT) in patients with locally-advanced NSCLC.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Intraoperative photodynamic therapy combined with novel proton radiation improved survival time significantly for recent patients with advanced-stage pleural mesothelioma. The study — the first to measure the impact of this combination — involved 10 consecutive patients treated at the University of Pennsylvania’s Abramson Cancer Center. The treatment regimen resulted in a 90 percent, two-year disease control rate and an impressive 30.3-month median overall survival from the time of diagnosis. All 10 patients were diagnosed before treatment began with stage 3 or stage 4 disease, which typically results in ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
We explored spatial dose patterns associated with symptomatic radiation pneumonitis (RP) in patients with non-small-cell lung cancer given either intensity-modulated photon therapy or passive scattering proton therapy. A dose distribution analysis highlighted regional dose differences associated with both RP status and treatment modality, showing that regions spared with protons are complementary to those correlated with RP; these results can be useful for clinical practice and for designing future trials to minimize RP.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Physics Contribution Source Type: research
Liver cancer is one of the most common causes of cancer-related deaths [1,2]. Radiotherapy for liver cancer is difficult because of the low tolerance of the liver to radiation, sparing of adjacent normal structures, respiratory motion, and challenges in localizing the intrahepatic target during radiotherapy [3 –6]. Compared with radiotherapy with photons, e.g., intensity-modulated photon therapy (IMRT), proton therapy is characterized by a sharp dose fall-off around the target volume. Therefore, proton therapy can deliver a higher dose to liver tumor while preserving much more normal liver tissue than I MRT [1].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Intensity Modulated Radiation Therapy (IMRT), Volumetric Modulated Arctherapy (VMAT) or other highly conformal techniques (e.g. proton therapy) are techniques that allow precise targeting of the volumes to be irradiated while protecting healthy tissue. In 2018, it is the standard method of irradiation of head and neck cancers [1 –5]. Because of their precision, these techniques require that each target volume be strictly and rigorously defined. The delineation and selection of these volumes is complex and requires a solid learning curve.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Guidelines Source Type: research
More News: Cancer | Cancer & Oncology | Intensity-Modulated Radiation Therapy | Japan Health | Proton Therapy